II. Indications
- Moderate to severe acute pain in adults
 
III. Contraindications
- Severe hepatic Impairment (Child-Pugh Class C)
- Reduce dose in moderate hepatic Impairment
 
 
IV. Mechanism
- Non-Opioid Analgesic with unique mechanism, released in 2024 at $15/pill
 - 
                          Sodium Channel Blocker developed for use in acute pain
- Specific for the voltage-gated Sodium channel Nav1.8 (SNS)
 - Nav1.8 is found primarily in nociceptive Neurons (primarily in the dorsal root Ganglion)
 - Blocks transmission of Peripheral Nerve pain sesnsation
 
 
V. Dosing
- First Dose: 100 mg orally on an empty Stomach (except clear liquids)
- May be taken with clear liquids (water, apple juice, tea or black coffee)
 - First dose should be taken >1 hour before or >2 hours after food
 
 - Subsequent Doses: 50 mg orally every 12 hours
- May be taken with or without food
 - May be used for up to 14 days (longer courses have not been studied)
 
 
VI. Adverse Effects
- Pruritus
 - Rash
 - Myalgias and Muscle spasms
- May be associated with increased Creatine Phosphokinase (CPK)
 
 
VII. Safety
- Avoid in pregnancy (unknown safety)
 - Avoid in Lactation (present in animal milk, unknown safety)
 
VIII. Drug Interactions
- 
                          CYP3A Inhibitors
- Avoid with use of strong CYP3A Inhibitors (e.g. Itraconazole)
 - Avoid Grapefruit juice while on Suzetrigine
 
 - 
                          CYP3A Inducers
- Avoid with moderate to strong CYP3A Inducers (e.g. Rifampin)
 
 - 
                          Progestins (other than Levonorgestrel or Norethindrone)
- If used for Contraception, use an alternate contracepive while taking Suzetrigine and for 28 days after
 
 
IX. Efficacy
X. Resources
XI. References
- (2025) Presc Insights, Issue 3/2025
 - LoVecchio (2025) Crit Dec Emerg Med 39(7): 34